HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

No investor will be happy with their GSK shares as the FTSE 100 pharmaceutical giant has had a dismal decade. Will the next ...

Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across ...

Aurobindo Pharma to manufacture and supply long-acting injectable HIV treatment in 133 countries, offering alternative to ...